vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Grand Canyon Education, Inc. (LOPE). Click either name above to swap in a different company.
Grand Canyon Education, Inc. is the larger business by last-quarter revenue ($308.1M vs $284.0M, roughly 1.1× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 28.1%, a 68.2% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 5.3%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 5.9%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Grand Canyon Education, Inc. (GCE) is an American for-profit corporation that provides services to universities, specializing in program development, online education, and operational support. Formerly affiliated with Grand Canyon University (GCU), a Christian university in Arizona, GCE became a separate publicly traded company in 2008.
ACAD vs LOPE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $308.1M |
| Net Profit | $273.6M | $86.7M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 35.1% |
| Net Margin | 96.3% | 28.1% |
| Revenue YoY | 9.4% | 5.3% |
| Net Profit YoY | 90.3% | 5.9% |
| EPS (diluted) | $1.61 | $3.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $308.1M | ||
| Q3 25 | $278.6M | $261.1M | ||
| Q2 25 | $264.6M | $247.5M | ||
| Q1 25 | $244.3M | $289.3M | ||
| Q4 24 | $259.6M | $292.6M | ||
| Q3 24 | $250.4M | $238.3M | ||
| Q2 24 | $242.0M | $227.5M | ||
| Q1 24 | $205.8M | $274.7M |
| Q4 25 | $273.6M | $86.7M | ||
| Q3 25 | $71.8M | $16.3M | ||
| Q2 25 | $26.7M | $41.5M | ||
| Q1 25 | $19.0M | $71.6M | ||
| Q4 24 | $143.7M | $81.9M | ||
| Q3 24 | $32.8M | $41.5M | ||
| Q2 24 | $33.4M | $34.9M | ||
| Q1 24 | $16.6M | $68.0M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 35.1% | ||
| Q3 25 | 12.8% | 6.9% | ||
| Q2 25 | 12.2% | 20.9% | ||
| Q1 25 | 7.9% | 30.4% | ||
| Q4 24 | 59.1% | 34.2% | ||
| Q3 24 | 12.6% | 20.2% | ||
| Q2 24 | 12.6% | 18.8% | ||
| Q1 24 | 7.4% | 30.8% |
| Q4 25 | 96.3% | 28.1% | ||
| Q3 25 | 25.8% | 6.2% | ||
| Q2 25 | 10.1% | 16.8% | ||
| Q1 25 | 7.8% | 24.8% | ||
| Q4 24 | 55.4% | 28.0% | ||
| Q3 24 | 13.1% | 17.4% | ||
| Q2 24 | 13.8% | 15.3% | ||
| Q1 24 | 8.0% | 24.8% |
| Q4 25 | $1.61 | $3.13 | ||
| Q3 25 | $0.42 | $0.58 | ||
| Q2 25 | $0.16 | $1.48 | ||
| Q1 25 | $0.11 | $2.52 | ||
| Q4 24 | $0.86 | $2.83 | ||
| Q3 24 | $0.20 | $1.42 | ||
| Q2 24 | $0.20 | $1.19 | ||
| Q1 24 | $0.10 | $2.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $111.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $746.9M |
| Total Assets | $1.6B | $992.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $111.8M | ||
| Q3 25 | $258.0M | $97.3M | ||
| Q2 25 | $253.6M | $192.3M | ||
| Q1 25 | $217.7M | $144.5M | ||
| Q4 24 | $319.6M | $324.6M | ||
| Q3 24 | $155.1M | $263.6M | ||
| Q2 24 | $177.1M | $241.3M | ||
| Q1 24 | $204.7M | $196.2M |
| Q4 25 | $1.2B | $746.9M | ||
| Q3 25 | $917.3M | $758.0M | ||
| Q2 25 | $822.4M | $778.0M | ||
| Q1 25 | $765.2M | $780.7M | ||
| Q4 24 | $732.8M | $783.9M | ||
| Q3 24 | $577.2M | $764.1M | ||
| Q2 24 | $516.7M | $759.2M | ||
| Q1 24 | $464.0M | $759.4M |
| Q4 25 | $1.6B | $992.3M | ||
| Q3 25 | $1.3B | $1.0B | ||
| Q2 25 | $1.2B | $1.0B | ||
| Q1 25 | $1.1B | $1.0B | ||
| Q4 24 | $1.2B | $1.0B | ||
| Q3 24 | $976.9M | $992.9M | ||
| Q2 24 | $914.1M | $992.7M | ||
| Q1 24 | $855.1M | $1.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $130.5M |
| Free Cash FlowOCF − Capex | — | $122.9M |
| FCF MarginFCF / Revenue | — | 39.9% |
| Capex IntensityCapex / Revenue | — | 2.5% |
| Cash ConversionOCF / Net Profit | -0.18× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | $238.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $130.5M | ||
| Q3 25 | $74.3M | $-48.6M | ||
| Q2 25 | $64.0M | $124.0M | ||
| Q1 25 | $20.3M | $67.6M | ||
| Q4 24 | $40.4M | $135.8M | ||
| Q3 24 | $63.2M | $-29.4M | ||
| Q2 24 | $25.0M | $98.6M | ||
| Q1 24 | $29.1M | $85.0M |
| Q4 25 | — | $122.9M | ||
| Q3 25 | $73.9M | $-58.3M | ||
| Q2 25 | — | $115.4M | ||
| Q1 25 | — | $58.7M | ||
| Q4 24 | — | $126.1M | ||
| Q3 24 | $63.2M | $-39.0M | ||
| Q2 24 | — | $89.6M | ||
| Q1 24 | — | $76.0M |
| Q4 25 | — | 39.9% | ||
| Q3 25 | 26.5% | -22.3% | ||
| Q2 25 | — | 46.6% | ||
| Q1 25 | — | 20.3% | ||
| Q4 24 | — | 43.1% | ||
| Q3 24 | 25.2% | -16.3% | ||
| Q2 24 | — | 39.4% | ||
| Q1 24 | — | 27.7% |
| Q4 25 | — | 2.5% | ||
| Q3 25 | 0.1% | 3.7% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 3.1% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | 0.0% | 4.0% | ||
| Q2 24 | — | 3.9% | ||
| Q1 24 | — | 3.3% |
| Q4 25 | -0.18× | 1.50× | ||
| Q3 25 | 1.03× | -2.99× | ||
| Q2 25 | 2.40× | 2.98× | ||
| Q1 25 | 1.07× | 0.94× | ||
| Q4 24 | 0.28× | 1.66× | ||
| Q3 24 | 1.93× | -0.71× | ||
| Q2 24 | 0.75× | 2.83× | ||
| Q1 24 | 1.76× | 1.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
LOPE
Segment breakdown not available.
